<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37672863</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0023</ISSN><JournalIssue CitedMedium="Internet"><Volume>171</Volume><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Cytokine</Title><ISOAbbreviation>Cytokine</ISOAbbreviation></Journal><ArticleTitle>Inflammatory and cytotoxic mediators in COVID-19 patients and in ChAdOx1 nCoV-19 (AZD1222) vaccine recipients.</ArticleTitle><Pagination><StartPage>156350</StartPage><MedlinePgn>156350</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cyto.2023.156350</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1043-4666(23)00228-4</ELocationID><Abstract><AbstractText>Immunological and cytotoxic mediators are induced in natural infection and are essential for the effectiveness of vaccination. Vaccination is useful to prevent the spread of SARS-CoV-2 and limit the morbidity/mortality of COVID-19. ChAdOx1 nCoV-19 is one of the most widespread vaccines in the world. We compared the detection of anti-S1 SARS-CoV2 IgG and the profile of inflammatory and cytotoxic responses of patients who developed different clinical outcomes of COVID-19 with individuals previously exposed or not to the virus received the first and booster doses of ChAdOx1 nCoV-19. Plasma from 35 patients with COVID-19 and 11 vaccinated were evaluated by multiplex assay. Here, no vaccinated subjects had serious adverse effects. Those vaccinated with a booster dose had higher anti-S1 IgG than mild/moderate and recovered patients. Critically ill and deceased patients had IgG levels like those immunized. By univariate analysis, IL-2, IL-17, and perforin do not differentiate between patients and vaccinated individuals. Granzyme A increased at dose 1, while patients had their levels reduced. High levels of granulysin, sFas, and IL-6 were detected in the deaths, but after vaccination, all were declined. The multivariate analysis supports the role of IL-6 and granulysin as associated and non-confounding variables related to the worst clinical outcome of COVID-19, but not sFas. Our data confirm the ability of the ChAdOx1 vaccine to produce specific antibody levels up to booster time. Furthermore, our data suggest that the vaccine can regulate both the hyper-production and the kinetics of the production of inflammatory and cytotoxic mediators involved in the cytokine storm, such as granulysin and IL-6.</AbstractText><CopyrightInformation>Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Familiar-Macedo</LastName><ForeName>Débora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: deborafamiliar@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieira Damasco</LastName><ForeName>Paulo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Rede Casa Hospital Rio Laranjeiras e Rio Botafogo, Rio de Janeiro 22240-000, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiestas Solórzano</LastName><ForeName>Victor Edgar</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: vicfiso@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carnevale Rodrigues</LastName><ForeName>Joyce</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sampaio de Lemos</LastName><ForeName>Elba Regina</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Laboratório de Hantaviroses e Rickettsioses, Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: elemos@ioc.fiocruz.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barreto Dos Santos</LastName><ForeName>Flávia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: flaviab@ioc.fiocruz.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agudo Mendonça Teixeira de Siqueira</LastName><ForeName>Marilda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratório de Vírus Respiratórios, Exantemáticos, Enterovírus e Emergências Virais (LVRE), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: mmsiq@ioc.fiocruz.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leal de Azeredo</LastName><ForeName>Elzinandes</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: elzinandes@ioc.fiocruz.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de-Oliveira-Pinto</LastName><ForeName>Luzia Maria</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Laboratório das Interações Vírus-Hospedeiros (LIVH), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz (IOC/Fiocruz), Rio de Janeiro 21040-360, Brazil. Electronic address: lpinto@ioc.fiocruz.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cytokine</MedlineTA><NlmUniqueID>9005353</NlmUniqueID><ISSNLinking>1043-4666</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>B5S3K2V0G8</RegistryNumber><NameOfSubstance UI="D000090985">ChAdOx1 nCoV-19</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014612">Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000090985" MajorTopicYN="N">ChAdOx1 nCoV-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014612" MajorTopicYN="Y">Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ChAdOx1 nCoV-19 Vaccine</Keyword><Keyword MajorTopicYN="N">Cytotoxic mediators</Keyword><Keyword MajorTopicYN="N">Inflammatory mediators</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37672863</ArticleId><ArticleId IdType="doi">10.1016/j.cyto.2023.156350</ArticleId><ArticleId IdType="pii">S1043-4666(23)00228-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle>